8-K: 180 Life Sciences Announces 1-for-19 Reverse Stock Split to Regain Nasdaq Compliance

180 Life Sciences Corp. will implement a 1-for-19 reverse stock split effective February 28, 2024, to meet Nasdaq's minimum bid price requirement.

Summary

• 180 Life Sciences Corp. has announced a 1-for-19 reverse stock split of its common stock.
• The reverse stock split is scheduled to take effect on February 28, 2024, at 12:01 p.m. Eastern Time.
• Trading on a split-adjusted basis will begin at market open on February 28, 2024.
• The reverse stock split aims to regain compliance with Nasdaq's minimum bid price requirement of $1.00 per share.
• The number of outstanding shares will decrease from approximately 11.3 million to approximately 0.6 million, subject to adjustments.
• All outstanding options, warrants, and other securities will be adjusted accordingly.
• The par value of the common stock will remain at $0.0001 per share.
• No fractional shares will be issued; instead, stockholders will receive one whole share in lieu of any fractional entitlement.

Sentiment

Score: 3

Explanation: The document primarily focuses on a reverse stock split, which is generally a negative indicator of a company's financial health. While the company is taking steps to maintain its listing, the underlying reason for the split is concerning.

Positives

• The reverse stock split is a strategic move to ensure continued listing on the Nasdaq Capital Market.
• The company is taking proactive steps to address compliance issues.
• The reverse split will not change the par value of the common stock or the authorized number of shares.

Negatives

• The reverse stock split is a consequence of the company's share price falling below Nasdaq's minimum bid price requirement.
• The reverse stock split will significantly reduce the number of outstanding shares.

Risks

• The company is not currently in compliance with Nasdaq's continued listing standards.
• There are risks associated with the outcome of pharmaceutical studies, the timing and costs thereof, and the ability to obtain sufficient participants.
• The company faces risks regarding the ability to commercialize drug candidates and obtain regulatory approvals.
• The company has current negative operating cash flows and needs additional funding to finance its operating plans.
• The terms of any further financing may be highly dilutive and may include onerous terms.

Future Outlook

The company aims to regain compliance with Nasdaq's minimum bid price requirement through the reverse stock split. The company also continues to focus on the development of therapeutics for unmet medical needs in chronic pain, inflammation and fibrosis.

Management Comments

• The Reverse Stock Split is part of the Company's plan to regain compliance with the minimum bid price requirement of $1.00 per share required to maintain continued listing on The Nasdaq Capital Market, among other benefits.

Industry Context

Reverse stock splits are a common strategy for companies facing delisting from major exchanges due to low share prices. This action is often a sign of financial distress or a need to improve the company's image to attract investors.

Comparison to Industry Standards

• Reverse stock splits are a common mechanism used by companies to maintain listing compliance, particularly in the biotechnology sector where stock prices can be volatile.
• Other companies in the biotechnology sector that have recently undertaken reverse stock splits include XOMA Corporation (XOMA) and Agenus Inc. (AGEN).
• The 1-for-19 ratio is relatively high compared to some reverse stock splits, which can range from 1-for-2 to 1-for-10, indicating a significant drop in the company's share price.

Stakeholder Impact

• Shareholders will see a reduction in the number of shares they own, but the value of their holdings should remain relatively constant immediately after the split.
• The reverse stock split is intended to maintain the company's listing on the Nasdaq, which is important for investor confidence.
• The company's ability to raise future capital may be affected by the reverse stock split.

Next Steps

• The reverse stock split will be effective on February 28, 2024.
• The company will file a Current Report on Form 8-K following the Effective Time.
• The company will continue to pursue its clinical development programs.

Key Dates

Keywords

reverse stock split, Nasdaq compliance, minimum bid price, stock split, ATNF, ATNFW, share consolidation, biotechnology, clinical stage